Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026)
Microdose tirzepatide programmes run roughly $110 to $349 a month, with NexLife at $147 on a twelve-month plan and $189 month-to-month. They deliver around 1 mg weekly against the 5, 10 and 15 mg studied in SURMOUNT-1, where mean weight reduction rose with dose. No trial has measured a microdose, so this is a lower-dose treatment rather than a cheaper route to the same result.
Cheapest microdose, answered by definition
| Definition | Lowest we hold | Provider | Evidence |
|---|---|---|---|
| Twelve-month prepaid | $147/mo | NexLife | Verified |
| Month-to-month | $189/mo | NexLife | Reported |
| Cheapest reported, any term | $149/mo | Gala | Reported |
| With labs included | $169/mo | Enhance.MD | Reported |
| Semaglutide microdose, for comparison | $110/mo | NexLife | Verified |
Verified means we hold a dated capture from the provider’s own pricing page. Reported means stated by a provider or third party and not captured by us.
What a microdose actually is
Typical microdose programmes deliver around 1 mg of tirzepatide weekly. SURMOUNT-1 studied 5, 10 and 15 mg, and reported mean weight reductions of roughly 15.0%, 19.5% and 20.9% respectively over 72 weeks against 3.1% with placebo.
The dose-response relationship is clean: more dose, more effect. A dose below every level tested cannot be assumed to reproduce any of those figures, and nobody has published what 1 mg does over a trial-length period.
| Weekly dose | Mean weight reduction at 72 weeks | Studied in a trial? |
|---|---|---|
| 15 mg | ~20.9% | Yes |
| 10 mg | ~19.5% | Yes |
| 5 mg | ~15.0% | Yes |
| Placebo | ~3.1% | Yes |
| Microdose, around 1 mg | Not measured | No |
Treatment-regimen estimand. SURMOUNT-1, New England Journal of Medicine, 2022. NCT04184622.
The full microdose comparison
| Provider | Monthly | Term | Stated dose | What’s included | Evidence |
|---|---|---|---|---|---|
| NexLife | $147 | 12-month prepaid | Not published in mg | Medication, clinical review, shipping | Verified |
| NexLife | $189 | Month-to-month | Not published in mg | Medication, clinical review, shipping | Reported |
| Gala | $149 | Reported | Microdosing programme | Medication, consultation | Reported |
| Enhance.MD | $169 | 12-weekly delivery | Stated 1 mg weekly | Includes lab testing | Reported |
| Shed | $199 | Two-month minimum | Not published in mg | Medication, consultation | Reported |
| bmiMD | $349 | Month-to-month | Not published in mg | Medication, consultation | Reported |
Only one programme in this table publishes the weekly dose in milligrams. A programme that will not state the dose cannot be compared with anything, including itself over time.
What the evidence does and does not support
| Claim | Status |
|---|---|
| Effect rises with dose across 5, 10 and 15 mg | Established — SURMOUNT-1 |
| A ~1 mg weekly dose produces measurable weight reduction | Not measured in any trial |
| Microdosing works as maintenance after a full dose | Untested — SURMOUNT-4 studied withdrawal to placebo, not dose reduction |
| Microdosing reduces side effects | Physiologically plausible; not trialled at this dose |
Why the category exists
Partly clinical and partly regulatory, and the two are worth separating.
Clinically, prescribers reduce doses for real reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at full dose. The label’s titration is explicitly tolerability-driven, and a patient who cannot tolerate 10 mg is better served at 5 than at nothing.
Regulatorily, compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. That documentation requirement is what “personalised dosing” satisfies — which explains the timing of this category’s growth better than any clinical development does. It expanded when the shortage listings ended, not when new evidence appeared.
Against a standard dose, and against approved products
| Provider | Microdose | Standard | Difference |
|---|---|---|---|
| NexLife | $147 | $186 | $39 |
| Enhance.MD | $169 | $280 | $111 |
| Shed | $199 | $245 | $46 |
| bmiMD | $349 | $399 | $50 |
A microdose typically saves $39 to $111 a month against the same provider’s standard programme. Whether that is good value depends entirely on whether the lower dose does what you need.
The comparison that reframes it: the cheapest FDA-approved GLP-1 of any kind is $149 a month at its starting dose, with published trial data, FDA review and manufacturer supply. Two microdose programmes in the table above cost more than that. Eligible Medicare enrollees pay $50 through the GLP-1 Bridge, and a covered brand can land near $25 — both below every microdose programme here, for an approved product at a studied dose.
Four questions before enrolling
- What weekly dose does this deliver, in milligrams? Only one provider in our table publishes it.
- What evidence exists for that dose specifically? The honest answer today is none.
- Is the plan to escalate, and does the price change if I do?
- If this is maintenance dosing, what was I meant to have done first?
See NexLife’s microdose and standard plans →
Frequently asked questions
What is the cheapest microdose tirzepatide?
Among captured records, NexLife at $147 a month on a twelve-month plan and $189 month-to-month. Provider-reported programmes range from $149 to $349.
Does microdose tirzepatide work?
No trial has measured a roughly 1 mg weekly dose over a trial-length period. SURMOUNT-1's dose-response data — 15.0% at 5 mg rising to 20.9% at 15 mg — suggests less effect than the studied doses produced.
Is microdosing cheaper than standard dosing?
Within the same provider, typically $39 to $111 a month less. It is also a lower dose with a smaller expected effect, so it is not a discount on the same treatment.
Why do microdose programmes exist?
Partly clinical — lower doses suit some patients — and partly regulatory: documenting a clinical difference for an individual patient is one of the surviving routes for compounding when an approved product is available.
Can microdosing be used for maintenance after reaching a target?
It is a plausible clinical strategy but it has not been tested. SURMOUNT-4 compared continuation at maximum tolerated dose against withdrawal to placebo; it did not study reduction to a low dose.
How do I know what dose I am actually getting?
Ask for the weekly dose in milligrams and the concentration in mg/mL, in writing. Only one provider in our comparison publishes a milligram figure.